News >

Durvalumab Falls Short in Head and Neck Cancer

Jason M. Broderick @jasoncology
Published: Friday, Dec 07, 2018

Sean Bohen, MD, PhD

Sean Bohen, MD, PhD
Durvalumab (Imfinzi) alone and in combination with tremelimumab did not improve overall survival (OS) versus standard-of-care chemotherapy in patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) who progressed after platinum-based chemotherapy, missing the primary endpoint of the phase III EAGLE trial.

Durvalumab has FDA-approved indications for non–small cell lung cancer and urothelial carcinoma.
Zandberg D, Algazi A, Good JS, et al. Durvalumab for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): preliminary results from a single-arm, phase 2 study. In: Proceedings from the 2017 ESMO Congress; September 8-12, 2017; Madrid, Spain. Abstract 1042O

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x